Newsroom
Sorted by: Latest
-
Asana to Appoint Aziz Megji to the Role of Chief Financial Officer
SAN FRANCISCO--(BUSINESS WIRE)--Asana, Inc. (NYSE: ASAN)(LTSE: ASAN), the system of action where humans and AI run work together, will promote Aziz Megji to the role of Chief Financial Officer (CFO), effective March 24, 2026. Megji will succeed Sonalee Parekh, who has served as Asana’s CFO since 2024 and tendered her resignation effective March 23, 2026. Megji brings his experience from his Head of Financial Planning & Analysis role where he led the company’s annual planning, budgeting, for...
-
Vitesse Energy Announces Signing of Accretive Acquisition, Fourth Quarter and Full Year 2025 Results, and Issues 2026 Production and Capital Expenditures Guidance
GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--Vitesse Energy, Inc. (NYSE: VTS) (“we,” “our,” “Vitesse,” or the “Company”) today announced an accretive all-stock acquisition, reported fourth quarter and full year 2025 financial and operating results, and issued 2026 guidance for production and capital expenditures. ACQUISITION Signed a definitive agreement to acquire non-operated assets in the Powder River Basin of Wyoming for $35 million of Vitesse common stock, with an effective date of January 1...
-
Asana Announces Fourth Quarter and Fiscal Year 2026 Results
SAN FRANCISCO--(BUSINESS WIRE)--Asana, Inc. (NYSE: ASAN) (LTSE: ASAN), the system of action where humans and AI run work together, today reported financial results for its fourth quarter and fiscal year ended January 31, 2026. “FY26 was a year of meaningful progress as we advanced Asana into a multi-product platform and strengthened our position as the foundational system of action layer for the Agentic Enterprise,” said Dan Rogers, Chief Executive Officer of Asana. “We exited Q4 with improving...
-
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally adopted a negative opinion regarding the Marketing Authorization Application for trofinetide for the treatment of Rett syndrome in patients two years of age and older. Acadia has reviewed the CHMP grounds for refusal in detail and intends to request a re-examination of the...
-
Credo Technology Group Holding Ltd Reports Third Quarter of Fiscal Year 2026 Financial Results
SAN JOSE, Calif.--(BUSINESS WIRE)--Credo Technology Group Holding Ltd (Credo) (Nasdaq: CRDO), an innovator in providing connectivity at scale through fast, reliable, and energy-efficient system solutions, today reported financial results for the third quarter of fiscal year 2026, ended January 31, 2026. Third Quarter of Fiscal Year 2026 Financial Highlights Revenue of $407.0 million, grew by 51.9% quarter over quarter and 201.5% year over year GAAP gross margin of 68.5% and non-GAAP gross margi...
-
Finward Bancorp Announces Dividend
MUNSTER, Ind.--(BUSINESS WIRE)--Finward Bancorp (Nasdaq: FNWD) (the “Bancorp” or “Finward”), the holding company for Peoples Bank (the “Bank”), today announced that on March 2, 2026 the Board of Directors of Finward declared a dividend of $0.12 per share on Finward’s common stock payable on March 31, 2026 to shareholders of record at the close of business on March 16, 2026. About Finward Bancorp Finward Bancorp is a locally managed and independent financial holding company headquartered in Muns...
-
Illumination Acquisition Corp I Announces Closing of $230,000,000 Initial Public Offering, Including Full Exercise of Underwriter’s Over-Allotment Option
NEW YORK--(BUSINESS WIRE)--Illumination Acquisition Corp I (Nasdaq: ILLUU) (the “Company”) announced today that it closed its initial public offering of 23,000,000 units, including the full 3,000,000 units subject to the underwriter’s over-allotment option, at $10.00 per unit. The offering resulted in gross proceeds to the Company of $230,000,000. The Company’s units are listed on the Nasdaq Global Market (“Nasdaq”) and commenced trading under the ticker symbol “ILLUU” on February 27, 2026. Eac...
-
Spruce Biosciences to Present at Upcoming Investor Conferences in March
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at two upcoming investor conferences taking place in March. Leerink Global Healthcare Conference Date and Time: March 9, 2026, at 11:20 a.m. ET Format: Firesid...
-
The St. Joe Company Releases the Latest Issue of “Watersound Lifestyle®,” the Watersound Club® Member Magazine
PANAMA CITY BEACH, Fla.--(BUSINESS WIRE)--The St. Joe Company (NYSE: JOE) (“Company”) releases the latest issue of Watersound Lifestyle, the Watersound Club member magazine. The biannual magazine provides insight into club amenities and highlights stories from the community. In this issue, readers can learn more about the many ways the Watersound Club experience is continuing to evolve—from signature events and traditions to generational club access and elevated retail. This issue also explores...
-
Sturm, Ruger & Company, Inc. Reports Fourth Quarter and Full-Year 2025 Results
MAYODAN, N.C.--(BUSINESS WIRE)--Sturm, Ruger & Company, Inc. (NYSE: RGR) (“Ruger” or the “Company”) announced today its financial results for the fourth quarter and full-year 2025. Fourth Quarter 2025 Financial Highlights The Company achieved fourth quarter net sales of $151.1 million, a 3.6% increase over the $145.8 million achieved in the corresponding period in 2024. For the fourth quarter, Ruger saw diluted earnings of $0.21 per share compared to $0.62 per share in the corresponding per...